Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

About
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

/

/

Orforglipron (Orforglipron) | Accelerate Your Fibrosis Research

Home/Drugs/Orforglipron

Orforglipron

Orforglipron

Phase 3

Sponsor: Eli Lilly

Indication: Obesity / MASH

Mechanism of Action

Oral GLP-1 Agonist

Target: GLP-1

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

ACTIVE_NOT_RECRUITINGNCT06972459

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Phase:PHASE3Org:Eli Lilly and Company

COMPLETEDNCT04680767

A Study of LY3502970 in Healthy Male Participants

Phase:PHASE1Org:Eli Lilly and Company

COMPLETEDNCT05313802

A Study of LY3502970 in Healthy Overweight and Obese Participants

Phase:PHASE1Org:Eli Lilly and Company

COMPLETEDNCT05931380

A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

Phase:PHASE3Org:Eli Lilly and Company

RECRUITINGNCT06948435

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Phase:PHASE3Org:Eli Lilly and Company

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

No recent publications found for Orforglipron.

Validated Models

This drug has been validated in the following preclinical models: